1 / 44

IGIV Therapy Overview and The ALPHA-TRAX TM Program

IGIV Therapy Overview and The ALPHA-TRAX TM Program. IGIV Therapy Outline. Evolution of IGIV Preparation of IGIV Viral Inactivation & Viral Partitioning Pharmacokinetics and Dosing of IGIV Safety of IGIV Therapy FDA-Approved Products ALPHA-TRAX TM Program Overview.

Audrey
Télécharger la présentation

IGIV Therapy Overview and The ALPHA-TRAX TM Program

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IGIV Therapy OverviewandThe ALPHA-TRAXTM Program

  2. IGIV Therapy Outline • Evolution of IGIV • Preparation of IGIV • Viral Inactivation & Viral Partitioning • Pharmacokinetics and Dosing of IGIV • Safety of IGIV Therapy • FDA-Approved Products • ALPHA-TRAXTM Program Overview

  3. Human Immunoglobulins Ig Class Serum Level Function mg/mL (%) IgG 1200 (77) Major Ig in Humans IgA 200 (13) Protects Mucosa IgM 150 (9) Major Ig for 1° Immune Response IgD 2 (<1) Regulates B Cells IgE <1 (trace) Major Ig in Allergic Response

  4. Evolution of IGIV Products • Intramuscular Route (IMIG): 1940s • First Generation IGIV: 1960s Non-intact Fab Fragments from Cleavage; Non-immune Modulatory • Second Generation IGIV: 1981Intact IgG Isolated After Secondary Fractionation of Fraction II • Third Generation IGIV: 1991Intact IgG with Intentional Viral Inactivation Steps: (eg, Solvent/Detergent Treatment, Pasteurization)

  5. IGIV Manufacturing Processes • Primary cold ethanol fractionation • Secondary fractionation may include: • Chemical modification • Incubation at pH 4.0 with or without pepsin • PEG precipitation • Ion-exchange chromatography • Enzymatic cleavage • Solvent detergent treatment • Diafiltration and ultrafiltration

  6. Plasma 0°C Cryosupernatant Cryoprecipitate 8% EtOH pH 7.0 -3°C Supernatant I Fraction I 21% EtOH pH 6.8 -5°C Fraction II + III Supernatant II + III 20% EtOH pH 6.7 -5°C Supernatant II + III w Fraction II + III w 17% EtOH pH 5.2 -5°C Supernatant III Fraction III 25% EtOH pH 7.4 -5°C Supernatant II Fraction II IgG Cohn-Oncley Isolation of IgG

  7. Guidelines for IGIV Products • Pool size 1,000 - 60,000 donors • Donor screening • High % of native monomeric IgG • Normal IgG subclasses • Low IgA content

  8. Donor Screening Limitations

  9. IgG Content of IGIV Preparations AlphaBaxterBayerCenteonNovartis Donor Pool10000 8000 2000 1000 16000 (minimum) IgG (%) > 99 > 90 > 98 > 99 > 96 IgG All Low All Low All Subclasses IgG4 IgG4 IgA (mcg/mL)22 < 3.7 270 25 720

  10. Reducing Viral Load Two methods to decrease viral load in plasma products: • Viral inactivation • Viral partitioning or removal

  11. Reducing IGIV Viral Load Examples of viral inactivation methods: • Cold ethanol fractionation • Heating (pasteurization) • Solvent/detergent • Acidic environment (low pH)

  12. Reducing IGIV Viral Load • Methods of viral partitioningor removal: • Cold ethanol fractionation • Phase partitioning or PEG precipitation • Affinity chromatography • Ion exchange or gel exclusion chromatography • Filtration (membrane barrier)

  13. Solvent/Detergent (SD) Process Basis for FDA licensure of SD process: Viral inactivation of antihemophilic factor (AHF) • Demonstrated inactivation of marker viruses • Effects against lipid-enveloped viruses • No adverse effect of SD on AHF proteins

  14. Virucidal Action of SD Process Demonstrated virucidal action against: • VSV (vesicular stomatitis virus) • Sindbis virus • HIV (human immunodeficiency virus) • HBV (hepatitis B virus) • HCV (hepatitis C virus NANBHV)

  15. SD Process is Selective Proteins unaffected by SD treatment: • Antihemophilic Factor (AHF; Factor VIII) • Factor IX • Fibrin • Fibrinogen • IgG • IgM

  16. Indications for IGIV Therapy Summary of FDA-Approved Uses*: • Primary Immune Deficiencies (PID) • Idiopathic Thrombocytopenic Purpura (ITP) • Chronic Lymphocytic Leukemia (CLL) • Kawasaki Disease • Bone Marrow Transplantation (BMT) • Pediatric HIV Infection * Not all IGIV products are approved for all indications

  17. FDA-Approved Indications Alpha Baxter Bayer Centeon Novartis PIDY Y Y Y Y ITPY Y Y N Y CLLN Y N N N Kawasaki Y Y N N N BMTN N Y N N Ped HIV N N Y N N

  18. Pharmacokinetics of IGIV • Half-Life and Dosing for PID • Kinetics are complex and variable • IGIV Has a biphasic elimination Distribution ( phase) 3-5 days Elimination ( phase) 3-4 weeks • Dosage and administration (usual dose) 200 mg/kg once monthly • If clinical response is considered inadequate: 300-400 mg/kg once monthly or more frequently

  19. Safety of IGIV Therapy Recommended Infusion Rates from Package Inserts Product Initial Rate Maximum Rate (for 1st 30 min.) (as tolerated) Alpha TherapeuticVenoglobulin®-S (5% Solution) 0.01-0.02 mL/kg/min 0.08 mL/kg/min (10% Solution) 0.01-0.02 mL/kg/min 0.05 mL/kg/min BaxterGammagard®S/D 0.01 mL/kg/min 0.08-0.13 mL/kg/minBayer Gamimune®N 0.01 mL/kg/min 0.08 mL/kg/min Centeon Gammar®-P I.V. 0.01 mL/kg/min 0.03-0.06 mL/kg/min Novartis Sandoglobulin® 0.5-1.0 mL/min 1.5-2.5 mL/min

  20. Safety of IGIV Therapy Adverse Effects • Pallor, chills, and sweating • Nausea and vomiting • Low-grade fever • Back or muscle pains • Tachycardia and chest tightening • Blood pressure changes • Wheezing • Rash/hives • Tachypnea • General malaise • Aseptic meningitis syndrome • Acute renal failure (ARF)

  21. Safety of IGIV Therapy Adverse Effects of IGIV Dosage (Potential Viral Transmission) • Multiple reports of HCV transmission from IGIV without intentional viral inactivation steps • Specific product recalls • FDA now recommends validated viral inactivation or removal for IGIV manufacturing

  22. Safety of IGIV Therapy • Previous anaphylactic reaction to IGIV or IMIG • Allergies to formulation ingredients • Selective deficiency in IgA IGIVContraindications Patients with:

  23. Safety of IGIV Therapy Drug Interactions • Antibodies in IGIV may interfere with response to live attenuated viral vaccines: Measles vaccine Mumps vaccine Rubella vaccine • Immunizing physicians should be informed of recent IGIV therapy so that appropriate precautions may be taken.

  24. IGIV Product Comparison Added Viral Inactivation Form Product(s) Osmolarity (mOsm/L) Alpha Baxter Bayer Centeon Novartis IgA Content (µg/mL) Venoglobulin®-S 5% Sorbitol SD 5%:15 5%: 300 liquid PEG/Bentonite 10%:20-50 10%:330 Gammagard® S/D Dry SD <3.7 5%: 636 Polygram® S/D 10%: 1250 Gamimune®-N 10% glycine SD 270 5%: 305 liquid pH4.0 10%: 274 Gammar®-P I.V. Dry Pasteurization 25.0 339-354 Sandoglobulin® Dry Unknown 720 6%: 690 NaCl Panglobulin® 12%:1074 NaCl 6%:384 H2O 12%:768 H2O

  25. IGIV Product Shortage Reasons for IGIV Product Shortage • Increased usage • Better diagnosis and increased off-label use • GMP-related production shutdowns • Impact of CJD withdrawal

  26. IGIV Product Shortage Conservation Guidelines for IGIV • Develop IGIV-use criteria • Use alternative therapy when possible • Decrease waste (round down dosage) • Adjust dose and frequency to IgG level rather than by weight/time for replacement • Reserve supply for high-risk patients Seigel J. Intravenous immune globulin. Pharm Prac News. 1999;March: 21-23.

  27. IGIV Product InformationConclusion • Immunoglobulin use is important in several disease states • IGIV has several advantages over IGIM • Food for thought: How can we ensure that all IGIV products are used safely and effectively?

  28. ALPHA-TRAXTM Program Overview 300001 .01-.02 mL/kg/min for 1st 30 min 100002 700000

  29. ALPHA-TRAXTM Program Overview 300001 700000 100002 .01-.02 mL/kg/min for 1st 30 min Comments Warnings Information

  30. ALPHA-TRAXTM Program Overview • ALPHA-TRAX Program Features: • Tracks lot numbers back to patients • Calculates infusion rates • Displays key product messages and reminders • Privately organizes patient information and provides easy access to data

  31. ALPHA-TRAXTM Program Main Menu

  32. ALPHA-TRAXTM Program Inventory Entry

  33. ALPHA-TRAXTM Program Patient Infusion

  34. ALPHA-TRAXTM Program Patient Infusion (cont.)

  35. ALPHA-TRAXTM Program Patient Infusion (cont.)

  36. ALPHA-TRAXTM Program Reports

  37. ALPHA-TRAXTM Program Reports (cont.)

  38. ALPHA-TRAXTM Program Edit Patients

  39. ALPHA-TRAXTM Program Edit Inventory

  40. ALPHA-TRAXTM Program Conclusions • Tracks lot numbers back to patients in case of recall or other product action • Calculates infusion rates (for Venoglobulin-S products only) • Displays key product messages and reminders on how to use the products effectively • Organizes product and patient information in reports that can be printed out

More Related